Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Prediction of Future Weight Change With Dopamine Transporter

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03146429
Recruitment Status : Completed
First Posted : May 10, 2017
Last Update Posted : April 24, 2018
Sponsor:
Information provided by (Responsible Party):
Kyoungjune Pak, Pusan National University Hospital

Brief Summary:
This is the re-analyzing study of observational study by Parkinson's Progression Markers Initiative

Condition or disease Intervention/treatment
Weight Change, Body Diagnostic Test: I-123 FP-CIT Single photon emission tomography

Layout table for study information
Study Type : Observational
Actual Enrollment : 200 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Prediction of Future Weight Change With Dopamine Transporter
Study Start Date : January 1, 2017
Actual Primary Completion Date : April 15, 2017
Actual Study Completion Date : April 15, 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Body Weight


Intervention Details:
  • Diagnostic Test: I-123 FP-CIT Single photon emission tomography
    Brain scan for dopamine transporter


Primary Outcome Measures :
  1. Weight change [ Time Frame: 1, 2, 3, 4, 5 year after SPECT ]
    weight change per year until 5 years after SPECT



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   30 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
The study population consisted of 192 healthy controls with screening 123I-FP-CIT SPECT.
Criteria

Inclusion Criteria:

  • males or females with their age of 30 years or older at screening

Exclusion Criteria:

  • subjects with a neurological disorder, a first degree relative with idiopathic PD, Montreal Cognitive Assessment score of 26 or less, medications that might interfere with DAT SPECT scans, anticoagulants that might preclude safe completion of the lumbar puncture, or investigational drugs, and a condition that precludes the safe performance of routine lumbar puncture

Layout table for additonal information
Responsible Party: Kyoungjune Pak, Clinical Assistant Professor, Pusan National University Hospital
ClinicalTrials.gov Identifier: NCT03146429     History of Changes
Other Study ID Numbers: PusanNUH-2017
First Posted: May 10, 2017    Key Record Dates
Last Update Posted: April 24, 2018
Last Verified: April 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Body Weight Changes
Body Weight
Signs and Symptoms
Dopamine
Cardiotonic Agents
Sympathomimetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Protective Agents